{"Clinical Trial ID": "NCT00482391", "Intervention": ["INTERVENTION 1:", "AC, PACLITAXEL, TRASTUZUMAB AND LAPATINIB", "Treatment consists of CA (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is administered subcutaneously (SQ) on day 2 of each CA. Filgrastim can be used instead of pegfilgrastim at the discretion of the doctor. Trastuzumab will be administered weekly from the start of paclitaxel treatment #1. Near the end of chemotherapy, patients can receive trastuzumab at one time q 3 weeks from the beginning of paclitaxel cycle #12. The total duration of trastuzumab from start to end of treatment is 52 weeks."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Adenocarcinoma of the breast confirmed histologically", "\u2022 Allowed bilateral synchronous breast tumours", "Any nodal status or tumour size allowed", "No stage IV disease", "HER2/Neu-positive disease", "3+ by IHC or amplified by FISH", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "Men or women", "\u2022 Menopausal status not specified", "ECOG Performance Status 0-1", "Absolute number of neutrophils 1,000/mm3", "Number of platelets 100 000/mm3", "Bilirubine 1.1 mg/dL", "- SGOT or SGPT 2.5 times the upper limit of normal (ULN)", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and after completion of the study.", "LVEF 50% by MUGA Scanner", "No peripheral neuropathy > grade 1", "No second active malignancy in the last 5 years, except for properly treated non-melanoma skin cancer or in situ cervix carcinoma", "No known allergies or hypersensitivity to doxorubicin hydrochloride, cyclophosphamide, paclitaxel or other medicinal products formulated in Cremophor EL", "No psychiatric illness or concomitant medical condition that would prevent treatment under study", "No other conditions, including any of the following:", "A unstable angina", "Congestive heart failure", "Myocardial infarction in the last 12 months", "High-risk uncontrolled arrhythmias (e.g., ventricular tachycardia, high-quality AV block or supraventricular arrhythmias that are not adequately controlled)", "No QT interval prolongation (> 500 ms)", "No active infection not resolved", "No sensitivity to E. coli-derived proteins", "THERAPE PRIOR CONCURENT:", "\u2022 Prior hormonal treatment for chemoprevention is allowed", "No anterior trastuzumab (Herceptin\u00ae)", "No anterior anthracycline", "No concomitant hormonal therapy, including hormonal contraception (e.g., ovarian contraceptive or hormonal pills or replacement therapy)", "No other chemotherapy, radiotherapy, immunotherapy or concomitant biotherapy for breast cancer", "No concomitant medicinal products that can prolong the QT interval"], "Results": ["Performance measures:", "Number of patients who have completed all planned treatments", "The number of patients who have completed all treatment regimens (adjuvant/neoadjuvant dose-sense chemotherapy) in patients with breast cancer overexpressed/ amplified by HER-2/neu.", "Time limit: 2 years", "Results 1:", "Title of the arm/group: AC, PACLITAXEL, TRASTUZUMAB & LAPATINIB", "The dosage regimen is composed of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is administered subcutaneously (SQ) on day 2 of each AC. Filgrastim can be used instead of pegfilgrastim at the discretion of the physician. Trastuzumab will be administered weekly from the start of paclitaxel treatment #1. Near the end of chemotherapy, patients can receive trastuzumab at a schedule of q 3 weeks from the beginning of the paclitaxel cycle #12. The total duration of trastuzumab from start to end of treatment is 52 weeks.", "Total number of participants analysed: 92", "Type of measurement: Number", "Unit of measurement: participants 45"], "Adverse Events": ["Undesirable Events 1:", "Total: 23/95 (24.21 per cent)", "Member State 1/95 (1.05%)", "Hematoma 1/95 (1.05%)", "Hemoglobin 2/95 (2.11 %)", "- Leukocytes (total WBC) 1/95 (1.05%)", "Hypertension 1/95 (1.05%)", "Hypotension 2/95 (2.11 %)", "- Left ventricular diastolic dysfunction 1/95 (1.05%)", "- Extended QTc interval 1/95 (1.05%)", "Sinus tachycardia 1/95 (1.05%)", "Ocular/Visual - Other (specify) 1/95 (1.05 %)"]}